Navigation Links
Intarcia Announces FDA Filing Acceptance of New Drug Application (NDA) for ITCA 650 for the Treatment of Type 2 Diabetes
Date:2/4/2017

BOSTON, Feb. 3, 2017 /PRNewswire/ -- Intarcia Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for active review its New Drug Application (NDA) for ITCA 650, an investigational therapy for the treatment of type 2 diabetes (T2D). Intarcia looks forward to working closely with the FDA through the review process.

ITCA 650 provides continuous delivery of exenatide via an osmotic mini-pump placed just beneath a patient's skin in the abdominal wall. It is designed to do this by leveraging Intarcia's innovative and proprietary technology, the Medici Drug Delivery System™. In studies, ITCA 650 mini-pumps were given with a 20mcg/day three-month introductory dose and then followed by a 60mcg/day six-month maintenance dose, which translates to twice-yearly dosing after initiation.

About Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment and prevention outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. Delivering medicines just once- or twice yearly to prevent and/or chronically treat diseases holds potential to improve outcomes by improving effectiveness over time and by addressing real-world unmet needs around poor patient adherence and persistence rates that are high in the majority of chronic diseases. Intarcia is investigating multiple therapies, including combination therapies, for chronic diseases leveraging the convergence of novel medicines and the proprietary Medici Drug Delivery System™. Intarcia is developing a strong pipeline in important therapeutic areas, including: diabetes, obesity, autoimmune diseases, HIV, and other serious disorders.
For more information on the Company, please visit www.intarcia.com.

Intarcia and its logo are registered trademarks of Intarcia Therapeutics, Inc.
Follow us on Twitter @intarcia.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/intarcia-announces-fda-filing-acceptance-of-new-drug-application-nda-for-itca-650-for-the-treatment-of-type-2-diabetes-300402157.html


'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Intarcia and Calibr Announce Collaboration and In-Licensing Deal Aimed at Delivering a Next Generation Combination Product for Diabetes and Obesity
2. Intarcia Therapeutics Announces Upcoming Presentation at 35th Annual J.P. Morgan Healthcare Conference
3. Intarcia Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of ITCA 650 in Type 2 Diabetes
4. Intarcia Appoints Dr. John Yee into New Role of VP, Global Medical Affairs, Safety and Operations, Reporting Directly to Chairman & CEO Kurt Graves
5. Intarcia Therapeutics Announces Upcoming Presentation at 34th Annual J.P. Morgan Healthcare Conference
6. Intarcia Announces New Top-Line Phase 3 Results For Investigational Therapy ITCA 650 In Type 2 Diabetes
7. Intarcia Announces Presentations At ADA Of Two Successful FREEDOM Phase 3 Trials For ITCA 650 -- A GLP-1 RA For Type 2 Diabetes
8. Intarcia To Announce Key ITCA 650 Phase 3 Findings And Other Data Presentations At Upcoming 75th Scientific Sessions of the American Diabetes Association In Boston
9. Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million
10. Intarcia Named To "CNBC Disruptor 50" List: One Of Only Two Biopharma Companies Named
11. Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017  PMD ... OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... strategic hub service that expedites and streamlines patient and ... Spiro PD 2.0, and wellness management services.  ... medical device used to measure lung function for a ...
(Date:9/12/2017)... -- Consumer reviews on the independent review site Consumer Affairs ... for hearing aids, ranking it higher than Miracle Ear ™, ... ... Hearing Aids ... store that provides high performance, state-of-the-art, German-engineered hearing aids directly to ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing an ... to overcome a rare and deadly chromosome abnormality. , After struggling since birth ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... a national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel ... also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
Breaking Medicine News(10 mins):